A detailed history of Price T Rowe Associates Inc transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 4,466,137 shares of PCVX stock, worth $395 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
4,466,137
Previous 3,173,167 40.75%
Holding current value
$395 Million
Previous $240 Million 112.99%
% of portfolio
0.06%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$70.52 - $117.12 $91.2 Million - $151 Million
1,292,970 Added 40.75%
4,466,137 $510 Million
Q2 2024

Aug 14, 2024

SELL
$60.06 - $78.77 $181,020 - $237,412
-3,014 Reduced 0.09%
3,173,167 $240 Million
Q1 2024

May 15, 2024

BUY
$59.79 - $81.05 $29.8 Million - $40.4 Million
498,359 Added 18.61%
3,176,181 $217 Million
Q4 2023

Feb 14, 2024

BUY
$45.35 - $63.41 $11.8 Million - $16.5 Million
260,170 Added 10.76%
2,677,822 $168 Million
Q3 2023

Nov 14, 2023

BUY
$46.0 - $53.1 $10.4 Million - $12 Million
225,270 Added 10.28%
2,417,652 $123 Million
Q2 2023

Aug 14, 2023

BUY
$34.66 - $54.07 $74.9 Million - $117 Million
2,160,354 Added 6745.2%
2,192,382 $109 Million
Q1 2023

May 15, 2023

BUY
$36.27 - $47.2 $63,835 - $83,072
1,760 Added 5.81%
32,028 $1.2 Million
Q4 2022

Feb 14, 2023

BUY
$20.58 - $47.95 $446,935 - $1.04 Million
21,717 Added 253.97%
30,268 $1.45 Million
Q3 2022

Nov 14, 2022

SELL
$21.69 - $28.53 $116,627 - $153,405
-5,377 Reduced 38.61%
8,551 $206,000
Q2 2022

Aug 15, 2022

BUY
$17.68 - $26.58 $21,569 - $32,427
1,220 Added 9.6%
13,928 $303,000
Q1 2022

May 16, 2022

BUY
$17.46 - $26.36 $19,677 - $29,707
1,127 Added 9.73%
12,708 $307,000
Q4 2021

Feb 14, 2022

SELL
$19.32 - $26.45 $15,456 - $21,160
-800 Reduced 6.46%
11,581 $276,000
Q3 2021

Nov 15, 2021

BUY
$20.26 - $26.97 $41,370 - $55,072
2,042 Added 19.75%
12,381 $314,000
Q2 2021

Aug 16, 2021

BUY
$16.45 - $24.06 $170,076 - $248,756
10,339 New
10,339 $233,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.25B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.